Tobacco companies are creating quite a steer, splitting investors into groups on Seeking Alpha. First group argues, the decline in smoking and younger, more health-conscious generations are clearly a warning sign to stay away from big tobacco as failure to hook-up youngstersI’m a Financial Analyst at a Fortune 500 company, investing with a long runway—30 years to retirement and plenty of compounding ahead. I write about building a thoughtful portfolio that balances strong growth potential with solid fundame ...

SAN DIEGO, June 30, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well ...

After stating early in my investment journey that I would never own an ETF, their explosive popularity gained my attention in recent months. I still prefer to invest in individual companies, but have recently analyzed several as potential additionsContributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encour ...

I recently covered Pony AI ( PONY ), which has developed autonomous vehicle (AV) technology at a far lower cost than Waymo. The economics of robotaxis are complex, given that the average US$12 fare needs to cover theExperience is difficult to learn. After 30 plus years of critically analyzing the nuts and bolts of businesses as diverse as airlines, oil, retail, mining to fintech and ecommerce plus the macro, monetary and political drivers. I continue to immensely enjoy learning and applying my experience to ...

Amsterdam, 30 June 2025 - Following a recent media publication, Azerion confirms that it is in discussions with DoubleU Games regarding a potential sale of Whow Games, a part of its Premium Games Segment. As already indicated to the market, Azerion remains committed to becoming the European leader in digital advertising. The company continues to manage its Premium Games Segment for value. While talks are ongoing with DoubleU Games regarding Whow Games, there is no agreement or certainty that they will ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Aegon Ltd. (AEG) is an insurance, pensions and asset management services company. The Zacks Consensus Estimate for its current year earnings has been revised 4.9% downward over the last 60 days.Apogee Enterprises, Inc. (APOG) is a glass and metal products and services company. The Zacks Consensus Estimate for its current year earnings has been revised nearly 8% downward over the last 60 days.Assertio Holdings, Inc. (ASRT) is a special ...

--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) --No other concerns stated, including pre-clinical, clinical, or safety data --The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Manufacturing and Controls (CMC) issues identified in the CRL --The Company plans to immediately request a Type A ...

Core Insights - Celcuity Inc. announced preliminary clinical data for gedatolisib in two early phase clinical trials, demonstrating promising efficacy and safety profiles in treating metastatic cancers [1][4][5] Phase 1 Clinical Trial in mCRPC - In the Phase 1 trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer (mCRPC), the six-month radiographic progression-free survival (rPFS) rate was reported at 66% [1][4] - The trial involved 38 patients, with two arms receiving different doses of gedatolisib (120 mg and 180 mg) alongside darolutamide [2] - No patients discontinued treatment due to treatment-related adverse events (AEs), and less than 3% experienced Grade 3 stomatitis [4][5] Phase 2 Clinical Trial in HER2+ Metastatic Breast Cancer - In the Phase 2 trial for HER2+ metastatic breast cancer (mBC), the objective response rate (ORR) was 43% among 44 patients treated with gedatolisib plus trastuzumab-pkrb [1][6] - The median number of prior anti-HER2 therapies for enrolled patients was four or more, with 86% having received at least three prior treatments [6] - No patients discontinued treatment due to treatment-related AEs, and no Grade 3 hyperglycemia was reported [5][6] Future Directions - The company plans to amend the clinical trial protocol to explore additional dosing options for gedatolisib in the ongoing Phase 1/1b trial [4] - Up to six patients will be enrolled in each of three arms to determine the recommended Phase 2 dose (RP2D), with a total of approximately 30 subjects expected to be treated with the RP2D in the Phase 2 dose expansion study [4][5] - Celcuity is also conducting other clinical trials, including a Phase 3 trial evaluating gedatolisib in combination with fulvestrant for HR+/HER2- advanced breast cancer [7]

Samuel Smith has a diverse background that includes being lead analyst and Vice President at several highly regarded dividend stock research firms and running his own dividend investing YouTube channel. He is a Professional Engineer and Project Management Professional and holds a B.S. in Civil Engineering & Mathematics from the United States Military Academy at West Point and has a Masters in Engineering from Texas A&M with a focus on applied mathematics and machine learning.Samuel leads the High Yield Inve ...

Core Insights - The article discusses several stocks that are expected to perform well in July, highlighting their momentum-driven price movements and positive outlooks for growth and cash flow [1] Group 1: Zscaler - Zscaler is noted as the most upgraded stock from Q1, with its cloud-native SaaS cybersecurity services aiding small and medium-sized businesses [1] - The company reported solid growth in the low 20% range, margin strength, and impressive guidance, prompting analysts to raise their forecasts [1][2] - The stock has seen a robust market response, with an approximately 85% gain from recent lows, indicating potential for further price increases [3][4] Group 2: Snowflake - Snowflake's FQ1 earnings report indicates strong business momentum and a sustained outlook for over 20% revenue growth [6][8] - Despite some downgrades, the overall analyst sentiment remains positive, leading to a solid Buy rating and rising consensus price target [7] - The stock is expected to break out of its long-term trading range, with a potential target near $350 by 2026 [8] Group 3: Dave & Buster's - Dave & Buster's is actively working on a business turnaround, with Q1 results showing sequential improvement and an optimistic outlook for growth and profitability [12][13] - Analysts have responded positively, with multiple price target increases following the FQ1 results, indicating a potential 25% gain [13] - The stock is approaching critical resistance levels, with expectations of reaching $40, which could trigger further inflows [14][15] Group 4: Oracle - Oracle has successfully transitioned into the cloud, with its cloud business thriving and expected to see substantial growth in 2026 [18][19] - The company is generating robust cash flow, which is being used for dividends and share buybacks [19] - Analyst trends are positive, with increased coverage and price target revisions suggesting potential for the stock to exceed $300 soon [20] Group 5: Advanced Micro Devices - Advanced Micro Devices is experiencing a rebound driven by AI, with expectations of nearly 40% top-line growth in Q2 [22][23] - The company is positioned for significant market share gains with the upcoming launch of the MI400 product [24] - Analysts have shown strong support through price target increases, indicating potential for a 40% upside [25]